Related Experiment Video
Updated: Nov 19, 2025
Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells
Published on: September 1, 2010
Medulloblastoma under Siege: Genetic and Molecular Dissection Concerning Recent Advances in Therapeutic Strategies
Zeal D Rawal1, Vinal A Upadhyay1, Dipak D Patel2
1Clinical Carcinogenesis Laboratory, Department of Cancer Biology, The Gujarat Cancer & Research Institute, Civil Hospital Campus, Ahmedabad, Gujarat, India.
Abstract:
Medulloblastoma (MB) is a devastating illness with unmet therapeutic needs, predominantly cytotoxic and nontargeted approaches. Survivors of MB also suffer from severe treatment-related effects of radiation and cytotoxic chemotherapy keeping mortality rate significant. Recently, four distinct molecular subgroups of MB have been identified (WNT [wingless], SHH [sonic hedgehog], Group 3, and Group 4). Novel subgroup-specific therapies are being explored in the daily treatment of patients as a clinical trial and are an important challenge in the near term for the pediatric neurooncology society. Epigenetic modifiers are also recurrently affected in MB suggesting that epigenetic therapy can be considered in a subset of patients. Moreover, a hint on forefront procedure; tracer of cancer's genetic information entitled "liquid biopsy" in MB is described. This review examines the recent scientific progress in MB research, with a focus on the genes, pathways that drive tumorigenesis and the advances in conventional and targeted therapy. The identification of subgroup-specific, actionable therapeutic targets has the potential to revolutionize therapy for patients with MB and results in significantly enriched overall survival.
Insights
Medulloblastoma research reveals four molecular subgroups, paving the way for targeted therapies. Advances in epigenetic therapy and liquid biopsy offer new hope for improving survival rates in this pediatric brain cancer.
Area of Science:
- Pediatric Neuro-oncology
- Cancer Genomics
- Molecular Biology
Background:
- Medulloblastoma (MB) presents significant therapeutic challenges, with current treatments causing severe side effects.
- Recent identification of four distinct molecular subgroups (WNT, SHH, Group 3, Group 4) offers new avenues for treatment.
- Epigenetic alterations are common in MB, suggesting potential for epigenetic-based therapies.
Purpose of the Study:
- To review recent scientific advancements in medulloblastoma research.
- To focus on genes, pathways driving tumorigenesis, and therapeutic strategies.
- To highlight novel approaches including subgroup-specific therapies, epigenetic modifications, and liquid biopsy.
Main Methods:
- Literature review of recent scientific progress in medulloblastoma research.
- Analysis of genetic drivers and molecular pathways implicated in medulloblastoma.
- Examination of conventional, targeted, and emerging therapeutic strategies.
Main Results:
- Four distinct molecular subgroups of medulloblastoma have been identified, each with unique characteristics.
- Subgroup-specific therapeutic targets are emerging, with potential for clinical trials.
- Epigenetic modifiers and liquid biopsy represent promising areas for future medulloblastoma treatment and diagnosis.
Conclusions:
- Targeted therapies based on medulloblastoma molecular subgroups hold the potential to revolutionize treatment.
- Advancements in epigenetic therapy and liquid biopsy may significantly improve patient outcomes and survival rates.
- Personalized treatment strategies are crucial for addressing the unmet therapeutic needs in medulloblastoma.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...